Skip to main content
. 2021 Oct 14;22(20):11057. doi: 10.3390/ijms222011057

Figure 2.

Figure 2

Co-activation of FcγRs and TLR2 enhances tumor cell killing by NK cells. ADCC experiments with the HNSCC cell lines (A) VU-SCC-096 (ADCC-sensitive) and (B) UM-SCC-47 (ADCC-insensitive) were performed with PBMCs (E:T ratio 60:1, 24 h incubation) or NK cells (E:T ratio 5:1, 4 h incubation). (A,B) Cetuximab (CTX, 0.5 µg/mL) was added in the absence or presence of agonists for TLR2/6 (Pam2CSK4, 5 µg/mL), TLR 1/2 (Pam3CSK4, 5 µg/mL) and TLR4 (LPS, 5 µg/mL), as indicated. Percentage (%) tumor killing in the treatment conditions was calculated compared to untreated conditions, where no cetuximab was added (no mab) (set at 0%). Bars represent mean ± SD; * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.0001, ns = not significant. (C) Representative images of NK cells co-cultured with VU-SCC-096 cells with or without cetuximab and/or Pam3CSK4 are shown. Pictures were taken from the culture wells with a Zeiss microscope fitted with camera using 10× magnification. The inserted magnifications in the top corners are digitally enlarged fields of the original 10× magnification.